Enhancing antibiotic activity: A strategy to control Acinetobacter infections

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 6, 2009, Pages 1203-1211

  Chusri, Sasitorn ^a   Villanueva, Ivan ^b   Voravuthikunchai, Supayang Piyawan ^a   Davies, Julian ^b  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Acinetobacter baumannii; Efflux pump inhibitors; Multidrug resistance; Natural products

Indexed keywords

AMIKACIN; AMINOCOUMARIN DERIVATIVE; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CATECHOL; CINNAMIC ACID; CIPROFLOXACIN; CLOROBIOCIN; COLISTIN; COUMAMYCIN; ELLAGIC ACID; ELLAGITANNIN; ERYTHROMYCIN; FERULIC ACID; FUSIDIC ACID; GALLIC ACID; GENTAMICIN; IMIPENEM; NEOMYCIN; NOVOBIOCIN; PARA COUMARIC ACID; QUERCETIN; RIFAMPICIN; SYRINGIC ACID; TANNIN; TETRACYCLINE; TOBRAMYCIN; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; 1 NAPHTHYLAMINE; ANTIINFECTIVE AGENT; DRUG DERIVATIVE; FLUORESCENT DYE; N (1 NAPHTHYL)ANILINE; N-PHENYL-1-NAPHTHYLAMINE; TANNIN DERIVATIVE;

ACINETOBACTER BAUMANNII; ADJUVANT THERAPY; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; CELL MEMBRANE; DRUG EFFECT; HUMAN; METABOLISM; METHODOLOGY; MICROBIAL VIABILITY; MICROBIOLOGICAL EXAMINATION; STAINING;

1-NAPHTHYLAMINE; ACINETOBACTER BAUMANNII; AMINOCOUMARINS; ANTI-BACTERIAL AGENTS; CELL MEMBRANE; DRUG SYNERGISM; ELLAGIC ACID; FLUORESCENT DYES; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; NOVOBIOCIN; STAINING AND LABELING; TANNINS;

EID: 76249093712     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp381     Document Type: Article

References (44)

1. Choi JY, Park YS, Kim CO et al. Mortality risk factors of Acinetobacter baumannii bacteraemia. Intern Med J 2005; 35: 599-603.
2. Lee NY, Lee HC, Ko NY et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 2007; 28: 713-19.
3. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006; 42: 692-9.
4. Giamarellou H, Antoniadou A, Kanellakopoulou K. Acinetobacter baumannii: a universal threat to public health? Int J Antimicrob Agents 2008; 32: 106-19.
5. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008; 46: 1254-63.
6. Robenshtok E, Paul M, Leibovici L et al. The significance of Acinetobacter baumannii bacteraemia compared with Klebsiella pneumoniae bacteraemia: risk factors and outcomes. J Hosp Infect 2006; 64: 282-7.
7. Damier-Piolle L, Magnet S, Bremont S et al. AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. Antimicrob Agents Chemother 2008; 52: 557-62.
8. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008; 8: 751-62.
9. Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother 2001; 45: 3375-80.
10. Vila J, Marti S, Sanchez-Cespedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J Antimicrob Chemother 2007; 59: 1210-15.
11. Hanlon GW. The emergence of multidrug resistant Acinetobacter species: a major concern in the hospital setting. Lett Appl Microbiol 2005; 41: 375-8.
12. Kwa AL, Loh C, Low JG et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005; 41: 754-7.
13. Maltezou HC. Metallo-b-lactamases in Gram-negative bacteria: introducing the era of pan-resistance? Int J Antimicrob Agents 2008; 33: 405.e1-7.
14. Mendes RE, Bell JM, Turnidge JD et al. Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. J Antimicrob Chemother 2009; 63: 55-9.
15. Levin AS, Barone AA, Penco J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-11.
16. Maxwell A. The interaction between coumarin drugs and DNA gyrase. Mol Microbiol 1993; 9: 681-6.
17. Anderle C, Stieger M, Burrell M et al. Biological activities of novel gyrase inhibitors of the aminocoumarin class. Antimicrob Agents Chemother 2008; 52: 1982-90.
18. Galm U, Heller S, Shapiro S et al. Antimicrobial and DNA gyrase-inhibitory activities of novel clorobiocin derivatives produced by mutasynthesis. Antimicrob Agents Chemother 2004; 48: 1307-12.
19. Cos P, Vlietinck AJ, Berghe DV et al. Anti-infective potential of natural products: how to develop a stronger in vitro 'proof-of-concept'. J Ethnopharmacol 2006; 106: 290-302.
20. Verpoorte R, Choi YH, Kim HK. Ethnopharmacology and systems biology: a perfect holistic match. J Ethnopharmacol 2005; 100: 53-6.
21. Neyfakh AA, Borsch CM, Kaatz GW. Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrob Agents Chemother 1993; 37: 128-9.
22. Schmitz FJ, Fluit AC, Luckefahr M et al. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1998; 42: 807-10.
23. Gibbons S, Udo EE. The effect of reserpine, a modulator of multidrug efflux pumps, on the in vitro activity of tetracycline against clinical isolates of methicillin resistant Staphylococcus aureus (MRSA) possessing the tet(K) determinant. Phytother Res 2000; 14: 139-40.
24. Gibbons S, Oluwatuyi M, Kaatz GW. A novel inhibitor of multidrug efflux pumps in Staphylococcus aureus. J Antimicrob Chemother 2003; 51: 13-7.
25. Hemaiswarya S, Kruthiventi AK, Doble M. Synergism between natural products and antibiotics against infectious diseases. Phytomedicine 2008; 15: 639-52.
26. Stavri M, Piddock LJ, Gibbons S. Bacterial efflux pump inhibitors from natural sources. J Antimicrob Chemother 2007; 59: 1247-60.
27. Wiegand I, Hilpert K, Hancock RE. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 2008; 3: 163-75.
28. Nohynek LJ, Alakomi HL, Kahkonen MP et al. Berry phenolics: antimicrobial properties and mechanisms of action against severe human pathogens. Nutr Cancer 2006; 54: 18-32.
29. Kern WV, Steinke P, Schumacher A et al. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli. J Antimicrob Chemother 2006; 57: 339-43.
30. Schumacher A, Steinke P, Bohnert JA et al. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Enterobacteriaceae other than Escherichia coli. J Antimicrob Chemother 2006; 57: 344-8.
31. Helander IM, Mattila-Sandholm T. Fluorometric assessment of gram-negative bacterial permeabilization. J Appl Microbiol 2000; 88: 213-9.
32. Savage PB. Multidrug-resistant bacteria: overcoming antibiotic permeability barriers of gram-negative bacteria. Ann Med 2001; 33: 167-71.
33. Alakomi HL, Paananen A, Suihko ML et al. Weakening effect of cell permeabilizers on gram-negative bacteria causing biodeterioration. Appl Environ Microbiol 2006; 72: 4695-703.
34. Khalil H, Chen T, Riffon R et al. Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008; 52: 1635-41.
35. Alakomi HL, Puupponen-Pimia R, Aura AM et al. Weakening of salmonella with selected microbial metabolites of berry-derived phenolic compounds and organic acids. J Agric Food Chem 2007; 55: 3905-12.
36. Chau SL, Chu YW, Houang ET. Novel resistance-nodulation- cell division efflux system AdeDE in Acinetobacter genomic DNA group 3. Antimicrob Agents Chemother 2004; 48: 4054-5.
37. Bohnert JA, Kern WV. Selected arylpiperazines are capable of reversing multidrug resistance in Escherichia coli overexpressing RND efflux pumps. Antimicrob Agents Chemother 2005; 49: 849-52.
38. Pannek S, Higgins PG, Steinke P et al. Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-b-naphthylamide. J Antimicrob Chemother 2006; 57: 970-4.
39. Amakura Y, Okada M, Tsuji S et al. Determination of ellagic acid in fresh and processed fruits by HPLC. J Food Hyg Soc Jpn 2000; 41: 206-11.
40. Pinto MDS, Lajolo FM, Genovese MI. Bioactive compounds and quantification of total ellagic acid in strawberries (Fragaria × ananassa Duch.). Food Chemistry 2008; 107: 1629-35.
41. Veklari SA, Gordon MH, Garcia-Macias P et al. Extraction and determination of ellagic acid content in chestnut bark and fruit. Food Chemistry 2008; 110: 1007-11.
42. Heber D. Multitargeted therapy of cancer by ellagitannins. Cancer Lett 2008; 269: 262-8.
43. Whitley AC, Stoner GD, Darby MV et al. Intestinal epithelial cell accumulation of the cancer preventive polyphenol ellagic acidextensive binding to protein and DNA. Biochem Pharmacol 2003; 66: 907-15.
44. Tasaki M, Umemura T, Maeda M et al. Safety assessment of ellagic acid, a food additive, in a subchronic toxicity study using F344 rats. Food Chem Toxicol 2008; 46: 1119-24.